Latest Headlines

  1. GE Healthcare And World Courier Collaborate To Drive Commercialization Of Cell And Gene Therapies

    GE Healthcare and World Courier, a part of AmerisourceBergen, are combining their expertise in manufacturing and logistics to better patient access to cell and gene therapies. Together, they aim to create a seamless end-to-end supply chain that will enable the developers of these treatments to meet increasing global demand.

  2. Helga Salling Traore Joins IPS As Regional Director, Southeastern US

    IPS-Integrated Project Services, LLC, a leading provider of engineering, procurement, construction management and validation (EPCMV) services, is pleased to announce the appointment of Ms. Helga Salling Traore to the position of Regional Director, Southeastern United States.

  3. Catalent To Acquire Gene Therapy Leader Paragon Bioservices, Inc. For $1.2B

    Catalent, Inc., the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies, recently announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2B.

  4. GenCure Selects G-CON Manufacturing PODs For New Biomanufacturing Facility

    GenCure has selected G-CON Manufacturing, the leader in prefabricated, flexible cleanroom solutions, for its new multi-product cell therapy facility

  5. G-CON Expands Into Europe With The Formation Of G-CON Manufacturing Europe Ltd

    G-CON Manufacturing, the leader in prefabricated, flexible cleanroom solutions, announced today that it has formed a new entity in Ireland, G-CON Manufacturing Europe Ltd.

  6. Bluebird Bio Opens New Gene Therapy Manufacturing Facility In North Carolina

    A gene therapy company that develops treatments for devastating diseases, bluebird bio Inc. opened its 125,000-square-foot manufacturing facility in Durham, North Carolina.

  7. CDMO Thermo Fisher Scientific Acquires Brammer Bio; Enters Cell & Gene Market

    Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, today announced they have entered into a definitive agreement under which Thermo Fisher will acquire Brammer Bio for approximately $1.7 billion in cash.

  8. Cellectis To Build New Manufacturing Facility In North Carolina ; French Plant In-Progress

    Cellectis , a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it has entered into a lease agreement to build an 82,000 square foot commercial-scale manufacturing facility named IMPACT (Innovative Manufacturing Plant for Allogeneic Cellular Therapies) in Raleigh, North Carolina, for clinical and commercial production of Cellectis’ leading allogeneic UCART products.

  9. Biogen To Purchase Gene Therapy Drug Manufacturer Nightstar Therapeutics For $800 Million

    Biogen Inc said on Monday it will buy Nightstar Therapeutics Plc for about $800M in cash as the company looks to tap into a potentially lucrative gene therapy market.

  10. Roche To Buy Spark Therapeutics For $4.8B

    Swiss drug maker Roche entered into a definitive agreement Monday to acquire Philadelphia gene therapy pioneer Spark Therapeutics in an all-cash deal valued at $4.8B.